Gerald T. Nepom

Gerald T. Nepom

Auto-generated profile, based on publicly available information

Gerald T. Nepom

Biomarker and Discovery Research, Immune Tolerance Network , San Francisco, CA

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2009 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JHJoachim Hallmayer
Joachim Hallmayer
JFJuliette Faraco
Juliette Faraco
LLLing Lin
Ling Lin
SHStephanie Hesselson
Stephanie Hesselson
JWJuliane Winkelmann
Juliane Winkelmann
EMEmmanuel Mignot
Emmanuel Mignot
Emmanuel Mignot and colleagues report that variants in the T-cell receptor alpha (TRA@) locus are strongly associated with narcolepsy. This is the first documented involvement of the TCR locus in human disease and will shed light on how HLA-TCR interactions contribute to organ-specific autoimmune targeting. Narcolepsy with cataplexy, characterized by sleepiness and rapid onset into REM sleep, affects 1 in 2,000 individuals1,2. Narcolepsy was first shown to be tightly associated with HLA-DR2 (ref. 3) and later sublocalized to DQB1*0602 (ref. 4). Following studies in dogs5 and mice6, a 95% loss of hypocretin-producing cells in postmortem hypothalami from narcoleptic individuals was reported7,8. Using genome-wide association (GWA) in Caucasians with replication in three ethnic groups, we found association between narcolepsy and polymorphisms in the TRA@ (T-cell receptor alpha) locus, with highest significance at rs1154155 (average allelic odds ratio 1.69, genotypic odds ratios 1.94 and 2.55, P < 10−21, 1,830 cases, 2,164 controls). This is the first documented genetic involvement of the TRA@ locus, encoding the major receptor for HLA-peptide presentation, in any disease. It is still unclear how specific HLA alleles confer susceptibility to over 100 HLA-associated disorders9; thus, narcolepsy will provide new insights on how HLA–TCR interactions contribute to organ-specific autoimmune targeting and may serve as a model for over 100 other HLA-associated disorders9.

16 April 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PCPatrick Concannon
Patrick Concannon
SRStephen S. Rich
Stephen S. Rich
GNGerald T. Nepom
Gerald T. Nepom
Genetic contributions to the cause of type 1 diabetes have been studied for more than 30 years, but only recently, with modern genetic tools, has the importance of seemingly minor contributors been appreciated. This article reviews recent advances in knowledge of the genetics of type 1 diabetes and shows how this information could find clinical applications of considerable consequence.

15 December 1999 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ENErik J. Novak
Erik J. Novak
ALAndrew W. Liu
Andrew W. Liu
GNGerald T. Nepom
Gerald T. Nepom
WKWilliam W. Kwok
William W. Kwok
Antigen-specific T helper cells present in peripheral blood at very low frequencies are capable of rapid clonal expansion during antigenic challenge. The exquisite specificity of this response provides for activation and expansion of a very select cohort of T cells, a feature we have used to directly identify and quantify human epitope-specific T helper cells from peripheral blood. Soluble tetramerized class II MHC molecules, loaded with an immunodominant peptide from hemagglutinin (HA) and labeled with fluorescent dyes, were constructed and used to directly identify antigen-specific T cells from influenza-immune individuals. After 7 days of proliferation in response to stimulation by HA peptide or whole influenza vaccine, cells staining positive with the HA tetramer had undergone between 6 and 9 divisions and were CD3+, CD4+, CD25+, and CD8–, characteristic of activated T helper cells responding to antigen. The HA epitope-specific component of the complex response to whole influenza vaccine represented a major subset of proliferating T helper cells. Soluble class II tetramers allow a direct approach for the analysis of immunodominant antigenic specificities. The identification of antigen-specific T helper cells in the peripheral blood provides a means for tracking the immune response against infectious agents and in autoimmune disease. This article may have been published online in advance of the print edition. The date of publication is available from the JCI website, http://www.jci.org. J. Clin. Invest.104:R63–R67 (1999).

1 April 2013 in Immunity
Verified
Journal Article
Closed access
GOGerlinde Obermoser
Gerlinde Obermoser
SPScott Presnell
Scott Presnell
KDKelly Domico
Kelly Domico
HXHui Xu
Hui Xu
YWYuanyuan Wang
Yuanyuan Wang
DCDamien Chaussabel
Damien Chaussabel

1 April 2010 in Immunity
Verified
Journal Article
Closed access
AZAnette-G. Ziegler
Anette-G. Ziegler
GNGerald T. Nepom
Gerald T. Nepom

20 July 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MRMark R. Rigby
Mark R. Rigby
KHKristina M. Harris
Kristina M. Harris
APAshley Pinckney
Ashley Pinckney
LDLinda A. DiMeglio
Linda A. DiMeglio
MRMarc S. Rendell
Marc S. Rendell
MEMario R. Ehlers
Mario R. Ehlers
BACKGROUND. Type 1 diabetes (T1D) results from destruction of pancreatic β cells by autoreactive effector T cells. We hypothesized that the immunomodulatory drug alefacept would result in targeted quantitative and qualitative changes in effector T cells and prolonged preservation of endogenous insulin secretion by the remaining β cells in patients with newly diagnosed T1D. METHODS. In a multicenter, randomized, double-blind, placebo-controlled trial, we compared alefacept (two 12-week courses of 15 mg/wk i.m., separated by a 12-week pause) with placebo in patients with recent onset of T1D. Endpoints were assessed at 24 months and included meal-stimulated C-peptide AUC, insulin use, hypoglycemic events, and immunologic responses. RESULTS. A total of 49 patients were enrolled. At 24 months, or 15 months after the last dose of alefacept, both the 4-hour and the 2-hour C-peptide AUCs were significantly greater in the treatment group than in the control group (P = 0.002 and 0.015, respectively). Exogenous insulin requirements were lower (P = 0.002) and rates of major hypoglycemic events were about 50% reduced (P < 0.001) in the alefacept group compared with placebo at 24 months. There was no apparent between-group difference in glycemic control or adverse events. Alefacept treatment depleted CD4+ and CD8+ central memory T cells (Tcm) and effector memory T cells (Tem) (P < 0.01), preserved Tregs, increased the ratios of Treg to Tem and Tcm (P < 0.01), and increased the percentage of PD-1+CD4+ Tem and Tcm (P < 0.01). CONCLUSIONS. In patients with newly diagnosed T1D, two 12-week courses of alefacept preserved C-peptide secretion, reduced insulin use and hypoglycemic events, and induced favorable immunologic profiles at 24 months, well over 1 year after cessation of therapy. TRIAL REGISTRATION. https://clinicaltrials.gov/ NCT00965458. FUNDING. NIH and Astellas.